April 8, 2009. We testified arguing that Seroquel, an Antipsychotic medication, should be kept off the market as it has not been conclusively proven that it does not increase the risk of diabetes or tardive dyskinesia.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Testimony on Seroquel XR
April 8, 2009. The benefits are statistically significant in most, but not all the studies provided to the FDA. But, let’s be clear here: the patients on placebo are improving greatly in these studies – almost as much as those taking Seroquel.
Read More »Comments to the Consumer Product Safety Commission on “Notice of Availability of Draft Guidance Regarding Which Children’s Products are Subject to the Requirements of CPSIA Section 108”
March 25, 2009. Our groups representing patient, consumer, science and public health interests submit the following comments regarding the draft approach prepared by CPSC staff for determining which products constitute a children’s toy or child care article and are subject to section 108 of the CPSIA.
Read More »Letter to U.S. Rep. Henry Waxman (Chairmen of the Energy and Commerce Committee) Supporting the “Ban Poisonous Additives Act of 2009″
March 18, 2009. The Centers for Disease Control and Prevention (CDC) found BPA in more than 90 percent of Americans tested for the chemical, and BPA is linked to numerous adverse health effects.
Read More »Letter to U.S. Senator Feinstein (CA) Strongly Supporting the “Ban Poisonous Additives Act of 2009”
March 18, 2009. The above members of the Patient and Consumer Coalition strongly support S. 593, the “Ban Poisonous Additives Act of 2009,” which will remove Bisphenol A (BPA) from food and beverage containers.
Read More »